---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-129007"
form_type: "8-K"
ticker: "IMNM"
cik: "0001472012"
company_name: "Immunome Inc."
filed_at: "2023-12-26T23:59:59+00:00"
generated_at: "2026-06-07T07:17:20.329304+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Immunome to acquire Atreca antibody assets for $5.5M upfront plus up to $7M milestones

## Summary
- Upfront cash payment of $5.5 million; additional $7.0 million in clinical development milestones.
- Assets include certain antibody-related assets and materials from Atreca, Inc.
- Transaction subject to customary conditions and Atreca stockholder approval.
- Immunome expects to expand its pipeline with the acquired assets.

## SEC filing metadata
- accession: 0001104659-23-129007
- form_type: 8-K
- ticker: IMNM
- cik: 0001472012
- company_name: Immunome Inc.
- filed_at: 2023-12-26T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1472012/000110465923129007/0001104659-23-129007-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1472012/000110465923129007/tm2333682d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-129007
- JSON: https://secwatch.observer/filing/0001104659-23-129007.json
- Plain text: https://secwatch.observer/filing/0001104659-23-129007.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.